North America In Vitro Diagnostics (IVD) Quality Control Market Analysis and Forecast, 2020-2035
The North America In Vitro Diagnostics (IVD) Quality Control Market is positioned for steady expansion driven by growing diagnostic requirements, stringent regulatory norms, and innovations in laboratory automation. With a marked shift towards precision medicine and advanced data management, the market is witnessing surging adoption of quality control products and digital solutions to ensure accuracy, compliance, and operational efficiency. The United States leads the region, with robust investments by companies and healthcare facilities accelerating technological upgrades. By 2025, the market size is estimated at 1,450 Million USD, expected to exceed 2,900 Million USD by 2035, reflecting a CAGR of 7.0%. Strategic collaborations, new product launches, and automated platforms underscore market dynamics, while competitive landscapes and tightening regulatory standards will shape future trajectory.
Latest Market Dynamics
Key Drivers
- Stringent regulatory guidelines for diagnostic accuracy and patient safety drive adoption of advanced quality control solutions. For instance, Bio-Rad Laboratories launched enhanced immunoassay controls in 2024 to meet updated CLIA requirements.
- Rising prevalence of chronic diseases increases diagnostic testing volumes, prompting labs to invest in quality control and data management. Abbott Laboratories introduced integrated informatics for hematology quality control in June 2024.
Key Trends
- Digitization of quality control processes is on the rise, with Thermo Fisher Scientific launching cloud-based QC platforms to streamline laboratory workflows across North America in July 2024.
- Growth in multi-analyte and multiplexed controls is observed, driven by demand for efficiency and comprehensive monitoring. Siemens Healthineers recently introduced multi-panel third-party controls in August 2024.
Key Opportunities
- Expansion into molecular diagnostics QC is a primary opportunity, capitalizing on the surge in genetic and infectious disease testing. Roche Diagnostics' 2024 portfolio extension to molecular QC marks a strategic move.
- Adoption of AI-driven analytics for QC data offers improved error tracking and predictive diagnostic quality. Randox Laboratories unveiled an AI-powered QC analytics dashboard in September 2024.
Key Challenges
- Integration challenges between legacy laboratory information systems and new digital QC platforms can slow adoption. Quidel Corporation faced deployment setbacks in cross-platform compatibility in recent hospital rollouts.
- Rising cost pressures due to high reagent and data management expenses impact small to medium diagnostic centers. Technopath Clinical Diagnostics observed lower conversion rates among cost-sensitive clients in 2025.
Key Restraints
- Complex regulatory approval processes delay product launches, as noted in ZeptoMetrix Corporation’s molecular control products pending FDA clearance since July 2024.
- Data privacy concerns and interoperability issues constrain the adoption of cloud-based QC solutions. Ortho Clinical Diagnostics reported data security compliance as a significant barrier in 2025 pilot projects.
Market Share by Type, 2025
Quality control products dominate the North America IVD QC market, supported by regulatory demands for rigorous laboratory validation. In 2025, Quality Control Products represent 42% of the market, underscoring the essential role of physical and software-based validation tools in diagnostics. Data Management Solutions, at 28%, reflect the sector’s shift toward automation and integrated reporting, while Quality Assurance Services account for 18%, emphasizing the need for ongoing compliance guidance and external benchmarking. Controls & Calibrators and Third-Party Quality Control round out the market at 7% and 5%, respectively. The growing reliance on informatics and external quality monitoring is reshaping industry standards.
Market Share by Application, 2025
Clinical Chemistry is projected to hold the largest share (30%) of the market in 2025, highlighting its foundational significance in laboratory diagnostics. Immunochemistry follows at 24%, fueled by increased testing for infectious and chronic diseases. Molecular Diagnostics sees a significant share at 20%, reflecting the shift towards genetic and pandemic-related testing. Hematology constitutes 14% of the market, while Coagulation and Microbiology collectively total 12%. The rising molecular diagnostics segment demonstrates demand for advanced QC tailored to new testing modalities, while immunochemistry's broad use in disease screening sustains its robust presence.
Market Revenue (USD Million), 2020-2035
Between 2020 and 2035, the North America IVD Quality Control Market is expected to register steady growth. The market was valued at 1,120 Million USD in 2020, rose to 1,450 Million USD in 2025, and is projected to reach 2,900 Million USD by 2035. This trend is attributed to continued healthcare investment, regulatory enforcement, and rising demand for advanced diagnostics across healthcare settings. Industry growth is supported by sustained technological innovation and heightened awareness about quality standards, ensuring robust expansion through the forecast period.
Market YOY Growth (%), 2020-2035
The market shows fluctuating year-on-year (YOY) growth rates, characteristic of a sector balancing regulatory adaptation with innovation cycles. YOY growth averaged 5% between 2020 and 2025, reached approximately 6% in the late 2020s, and is forecast to stabilize at around 7% through 2035. The projected growth is linked to new product launches, growing automation, and expanded application of molecular diagnostics. This incremental YOY expansion signals rising market maturity combined with continuous influxes of technological enhancements.
Market Share by Region, 2025
The United States remains the preeminent market, accounting for 76% of North America’s IVD Quality Control market share in 2025, buoyed by significant investments in healthcare infrastructure and regulatory compliance. Canada represents 15% of the market, reflecting steady QC adoption driven by universal healthcare and expanded lab networks. Mexico captures a 9% share, with rapid growth owing to increased spending in clinical diagnostics and evolving regulatory standards. All three markets collectively form an integrated North American landscape for IVD quality control, with the U.S. clearly leading in size and innovation.
Market Player Share, 2025
In 2025, Bio-Rad Laboratories dominates the North American IVD QC market with a 23% share, driven by extensive portfolio diversity and global reach. Siemens Healthineers and Abbott Laboratories account for 16% and 12% respectively, leveraging their technological advancements and established client bases. Thermo Fisher Scientific and Roche Diagnostics each capture approximately 8%, while the cumulative share held by all other players, including Randox Laboratories and Quidel Corporation, amounts to 33%. This competitive distribution underscores the market’s fragmentation, innovation-driven differentiation, and entry of niche QC providers.
Market Buyer Share, 2025
By 2025, large hospitals and clinical reference labs comprise over half (54%) of all IVD Quality Control purchases in North America due to higher test volumes and compliance needs. Medium-sized labs represent 27% of buyers, followed by small diagnostic centers and specialist clinics at 19%. Buyer concentration remains skewed towards large-scale institutions, but increasing penetration of automated QC solutions is encouraging adoption among smaller facilities, supporting market democratization and resilience.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 1450 |
| Regions | North America, US, Canada, Mexico |
| Segments | By Type (Quality Control Products, Data Management Solutions, Quality Assurance Services, Controls & Calibrators, Informatics Solutions, Third-Party Quality Control), By Application (Clinical Chemistry, Immunochemistry, Hematology, Molecular Diagnostics, Coagulation, Microbiology), By Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation), By Distribution Channels (Direct Sales, Distributors, Online Sales, Retail Pharmacies, E-commerce Platforms, Wholesalers), By Organization Size (Small, Medium, Large) |
| Players | Bio-Rad Laboratories, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., Abbott Laboratories, Randox Laboratories Ltd., Roche Diagnostics, Sero AS, Streck, Inc., Ortho Clinical Diagnostics, Helena Laboratories Corporation, ZeptoMetrix Corporation, Quidel Corporation, Sun Diagnostics, LLC, Microbiologics, Inc., Technopath Clinical Diagnostics |
Key Recent Developments
- July 2024: Thermo Fisher Scientific launches cloud-based QC management solution for North American laboratories, enabling real-time data integration and remote monitoring.
- June 2024: Abbott Laboratories introduces multi-channel hematology QC informatics system, supporting automated reporting and data-driven compliance.
- August 2024: Siemens Healthineers debuts multiplexed third-party controls for immunochemistry, addressing increased demand for comprehensive regulatory validation.
- September 2024: Randox Laboratories unveils an AI-powered QC analytics dashboard, enhancing error detection and proactive diagnostic monitoring.
- July 2024: ZeptoMetrix Corporation obtains Health Canada approval for molecular QC controls tailored to infectious disease diagnostics.
